Adaptin Bio (APTN) Equity Ratio (2022 - 2026)

Adaptin Bio's Equity Ratio history runs 5 years deep, the most recent figure standing at 2.51 for Q1 2026.

• In Q1 2026, Equity Ratio fell 511.2% year-over-year to 2.51; the TTM figure through Mar 2026 stood at 2.51 (down 511.2% YoY), while the FY2025 annual figure was 2.41, up 85.95% from the prior year.
• Equity Ratio came in at 2.51 for Q1 2026 at Adaptin Bio, down from 2.41 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.61 in Q1 2025 to a low of 10072.3 in Q3 2024.
• A 5-year average of 1918.93 and a median of 35.87 in 2024 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio tumbled 4760.78% in 2024 and soared 100.02% in 2025, its largest moves.
• Adaptin Bio's Equity Ratio stood at 54.61 in 2022, then slumped by 4610.89% to 2572.52 in 2023, then jumped by 99.33% to 17.13 in 2024, then jumped by 85.95% to 2.41 in 2025, then declined by 4.53% to 2.51 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 2.51, 2.41, and 0.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison